

Supplemental Data Table 1

Characteristics of Control Subjects and Subjects with Major Depressive Disorder (MDD)

A. Control Subjects

Subjects	Age/gender/race	Duration of illness (yrs)	PMI (hrs)	pH	Prescribed Medications	Toxicology	Smoker	Storage time (yrs)
C1	26/M/AA	NA	13	6.66	None	ND	No	15
C2	42/M/C	NA	20	6.82	None	ND	No	13
C3	44/M/C	NA	28	6.63	metoprolol	ND	Yes	7
C4	32/M/C	NA	25	6.88	PREDNISONE, AZATHIOPRINE METRONIDAZOL E MESALAMINE LOMOTIL	ND	No	7
C5	62/F/C	NA	27.5	6.34	None	ND	No	16
C6	45/F/AA	NA	9	6.86	None	ND	Yes	15
C7	50/F/C	NA	27	6.74	None	ND	Yes	12
C8	38/F/AA	NA	11	6.46	diltiazem, albuterol, prednisone	CO	Yes	11
C9	49/M/C	NA	10	6.71	None	CO	Yes	7
C10	65/F/C	NA	26	6.18	amlopidine, metoprolol	ND	No	8
C11	44/F/AA	NA	32	6.72	None	lidocaine	No	9
C12	80/F/C	NA	6.15	5.65	None	ND	No	19
C13	69/M/AA	NA	15	6.49	None	ND	No	11
C14	54/M/AA	NA	19	6.525	digoxin, dipyridamole	ND	No	15
C15	33/M/C	NA	23	6.86	None	ND	Yes	12
C16	47/M/AA	NA	27	6.09	None	EtOH	Yes	11
C17	46/M/AA	NA	11	6.95	None	ND	No	11
C18	67/M/C	NA	24	6.96	None	ND	Yes	11
Mean	Age: 49.6±3.4		19.6±1.9	6.58±0.08				11.7±3.4

B. Subjects with Major Depressive Disorder (MDD)

Subjects	Age/gender/race	Duration of illness (yrs)	PMI (hrs)	pH	Prescribed Medications	Toxicology	Smoker	Storage time (yrs)	Age of onset
MDD1	41/M/C	3	19.23	6.24	Possibly analgesics with codeine, chlorpheniramine	chlorpheniramine	Yes	9	~ 38
MDD2	43/M/C	15	21	6.73	None	ND	No	17	28
MDD3	47/M/C	20	11	6.84	None	EtOH	No	17	27
MDD4	62/M/C	3	20.2	6.47	bupirone, lorazepam	ND	Yes	19	59
MDD5	62/M/AA	3-27	22	6.1	None	ND	Yes	5	35
MDD6	68/M/C	NA	4	6.21	None	CO	No	18	NA
MDD7	80/M/C	0.4	21	6.67	None	ND	Yes	11	80
MDD8	78/F/C	15	25	6.94	lorazepam	ND	No	15	63
MDD9	81/F/C	2	29	6.695	None	ND	No	11	79
MDD10	83/F/C	4	21	6.32	TEMAZEPAM	ND	No	19	79
MDD11	46/M/AA	0.8	17	6.26	None	ND	No	15	45
MDD12	37/M/AA	1	31.5	6.7	None	EtOH	No	5	37
MDD13	38/F/C	5	12	6.41	SERTRALINE, DICYCLOMINE, TEMAZEPAM, diazepam	diazepam, temazepam	No	18	33
MDD14	36/F/AA	1	25	6.84	None	ND	Yes	13	35
MDD15	77/F/C	34	32	6.79	THIORIDAZINE, TRAZEDONE, VENLAFAXINE, diazepam, CLONAZEPAM	ND	No	16	27
MDD16	54/M/C	3	23	6.24	SERTRALINE, phenytoin, mysoline, protriptyline, perphenazine	CO, phenobarbital, phenytoin	Yes	15	39
MDD17	20/M/C	1	20	6.7	None	diphenhydramine	No	4	51
MDD18	30/M/AA	3	18	6.91	None	EtOH	Yes	16	20
Mean	Age: 54.6±4.7		20.7±1.6	6.56±0.06				13.5±1.2	

C. Diagnosis of Subjects with Major Depressive Disorder (MDD)

Subjects	Duration of illness (yrs)	Episode number	Episode duration (yrs)	Age of Onset
MDD1	3	1	3	~ 38
MDD2	15	2 to 3	0.06	28
MDD3	20	3	6	27
MDD4	3	1	3	59
MDD5	13	multiple	3	39
MDD6	NA	1	NA	NA
MDD7	0.4	1	0.4	80
MDD8	15	1	15	63
MDD9	2	1	4	79
MDD10	4	2	2	79
MDD11	0.8	1	.08	45
MDD12	1	1	1	37
MDD13	5	2 to 3	2	33
MDD14	1	1	1	35
MDD15	34	multiple	2	27
MDD16	3	1	3	39
MDD17	1	1	1	51
MDD18	3	1	3	20

Eighteen subjects were diagnosed with major depressive disorder (MDD) at the time of death according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 1995). Eighteen control subjects were assessed and diagnosed as psychiatrically normal. Additional information on subjects was gathered from medical records and coroner's records (including cause of death and toxicology reports). The toxicology reports revealed that the subjects with MDD were not treated with antidepressant medications immediately prior to death.

Medications listed under Prescribed Medications that are in upper case signify that the patient received the prescription within the last month of life; lowercase medications refer to other prescriptions the patient received during their lifetime prior to the last month of life.

AA, African American; C, Caucasian; F, female; M, male; NA, not available; PMI, postmortem interval (hours), defined as the time between death and freezing of the tissues; ND, nothing detected; CO, carbon monoxide; EtOH, ethanol level in blood.